RRC ID 78888
著者 Nomura TK, Heishima K, Sugito N, Sugawara R, Ueda H, Yukihiro A, Honda R.
タイトル Specific inhibition of oncogenic RAS using cell-permeable RAS-binding domains.
ジャーナル Cell Chem Biol
Abstract Oncogenic RAS proteins, common oncogenic drivers in many human cancers, have been refractory to conventional small-molecule and macromolecule inhibitors due to their intracellular localization and the lack of druggable pockets. Here, we present a feasible strategy for designing RAS inhibitors that involves intracellular delivery of RAS-binding domain (RBD), a nanomolar-affinity specific ligand of RAS. Screening of 51 different combinations of RBD and cell-permeable peptides has identified Pen-cRaf-v1 as a cell-permeable pan-RAS inhibitor capable of targeting both G12C and non-G12C RAS mutants. Pen-cRaf-v1 crosses the cell membrane via endocytosis, competitively inhibits RAS-effector interaction, and thereby exerts anticancer activity against several KRAS-mutant cancer cell lines. Moreover, Pen-cRaf-v1 exhibits excellent activity comparable with a leading pan-RAS inhibitor (BI-2852), as well as high target specificity in transcriptome analysis and alanine mutation analysis. These findings demonstrate that specific inhibition of oncogenic RAS, and possibly treatment of RAS-mutant cancer, is feasible by intracellular delivery of RBD.
巻・号 28(11)
ページ 1581-1589.e6
公開日 2021-11-18
DOI 10.1016/j.chembiol.2021.04.013
PII S2451-9456(21)00206-3
PMID 33964212
MeSH Animals Antineoplastic Agents / chemistry Antineoplastic Agents / pharmacology* Binding Sites / drug effects Cell Proliferation / drug effects Cell Survival / drug effects Drug Screening Assays, Antitumor Female Humans Male Mice Mice, Inbred BALB C Neoplasms, Experimental / drug therapy Neoplasms, Experimental / metabolism Neoplasms, Experimental / pathology Signal Transduction / drug effects Tumor Cells, Cultured ras Proteins / antagonists & inhibitors* ras Proteins / genetics
リソース情報
ヒト・動物細胞 HCT116(RCB2979) Colon-26(RCB2657)